UTv Videos

"In the last couple of years, there have been at least 2 sets of great tissue simulators that have come out, and I think they're really providing an opportunity for learning HoLEP," says Smita De, MD, PhD.

“People and patients are so much more informed now, and they're so engaged in their health. It's fantastic,” says Raevti Bole, MD.

“We were a bit surprised that the males with IC/BPS didn't look more like the females with regard to the magnitude of decrease in urinary symptom severity required to feel better,” says Alisa J. Stephens-Shields, PhD.

“These shortages and declines in supply have forced practitioners to readjust their diagnostic algorithms or at least question the usual practices,” says Jacob Taylor, MD, MPH.

"UH is working on starting clinics throughout rural Northeast Ohio, and we're meeting to develop a FPMRS program, both virtual and in-person, so patients can have access to this point of care," says David Sheyn, MD.

“Many were concerned that what the MIPS policy is really measuring is an ability to track and report measures as opposed to the actual provision of quality care,” says Avinash Maganty, MD.

“I am interested in looking at postpartum issues for sexual function,” says Rachel Pope, MD, MPH.

"The ultimate goal is to have as much of our time spent on actual patient care and complex decision-making [as possible]," says David Canes, MD.

"The overarching goal is to both increase the identification of patients with urinary incontinence as well as shorten the time between diagnosis and appropriate treatment," says David Sheyn, MD.

"We wanted to make sure that it was highlighted that men really need to be screened, and it should be covered by insurance," says Adam Murphy, MD, MBA, MSCI.

“I would have to say the most exciting part of the whole conference was how many medical students and trainees were there,” says Rachel Pope, MD, MPH.

“We found a significant increase in men under 30 getting vasectomies,” says Raevti Bole, MD.

Regardless of the type of chemotherapy regimen received, there was a benefit with the use of frontline avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma, explains Srikala S. Sridhar, MD.

"When we think about what burnout does to our workforce, the ramifications are significant," says Andrew M. Harris, MD.

"The future's bright, and I think we have a lot more people engaged," says Denise Asafu- Adjei, MD, MPH.

"There's a potential for a more nuanced approach to screening where you assess baseline at 40 for all races, so that you can then determine who needs to be screened regularly or not," says Adam Murphy, MD, MBA, MSCI.

“Whenever you're talking about the risk of incontinence, you should know your own data and not cite a specialist who has done a [large amount] of cases,” says Ricardo M. de Oliveira Soares, MD.

"Helping urologists establish practices in rural areas and incentivizing those practices is so important," says Kevin Koo, MD, MPH.

“There's a lot of talk about Roe v. Wade affecting the reproductive health of women. This implies that it's also affecting reproductive health decisions for men,” says Sarah Vij, MD.

“When I'm discussing surgery, or any kind of treatment for prostate cancer, with patients, I always talk about the ‘trifecta,’ “ says Ricardo M. de Oliveira Soares, MD.

“Major bladder reconstructive surgeries have the most room for improvement, particularly surgeries involving a bowel anastomosis,” says Sarah Hecht, MD.

“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.

“I think my biggest piece of advice would be to get a social worker into your clinic because there's so many things that we can do,” says Mara Markzon, LCSW, ACM-SW.

“What we found is that the majority of these companies…offered our ‘secret shopper’ testosterone therapy,” says Joshua A. Halpern, MD, MS.

“The biggest question that arose from this is, ‘Why is there such a lack of large familial genetic disorder epidemiological studies?’ says Laura Bukavina, MD, MPH.

“We need to continue to push the field forward, and the way we do that is to evaluate the risk factors and to stratify patients based on their risk factors and their genetic components,” says Laura Bukavina, MD, MPH.

Dr. Andre Goy gives insight into the center’s personalized experience discussing his approach to a patient’s treatment journey. Watch now.

Silver also outlines an example of a patient who he would treat with high-intensity focused ultrasound.

“The association between CKD and end-stage renal failure and increasing risk of kidney cancer is a really striking and important association to be aware of,” says Sarah P. Psutka, MD, MS.

“You can't just have all or none treatments. You've got to have a middle ground for people who are going to look for that,” says John R. Valvo, MD.